Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentationJuan Pablo Alderuccio, Izidore S. Lossos, Wei Zhao et al.|American Journal of Hematology|2019Cited by 36
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.Boyu Hu, Susan O’Brien, Houston Holmes et al.|Journal of Clinical Oncology|2024Cited by 19
POSTER: MM-441 The Efficacy and Safety of Cilta-Cel and Ide-Cel in Relapsed/Refractory Multiple Myeloma: A Meta-AnalysisSyed Imam Naufil, Muhammad Husnain, Zubair Amin et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
MM-441: The Efficacy and Safety of Cilta-Cel and Ide-Cel in Relapsed/Refractory Multiple Myeloma: A Meta-AnalysisSyed Imam Naufil, Muhammad Husnain, Zubair Amin et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Vispa-Cel, an Allogeneic Anti-CD19 CAR-T cell Therapy with a PD-1 Knockout, In Patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL): Updated Results from the Antler Phase 1 Clinical TrialMehdi Hamadani, Susan O'Brien, Houston Holmes et al.|Transplantation and Cellular Therapy|2026Cited by 0